-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In patients with systemic lupus erythematosus (SLE), a higher frequency of atherosclerotic lesions is associated with poor prognos.
Hydroxychloroquine (HCQ) has been reported to improve lifespan and dyslipidemia outcomes in SLE patients, but the mechanism is unclear
Methods: The study included SLE patients who received supplemental HCQ between January 2016 and September 2020 and maintained low disease activi.
method:
Serum adipokine levels before and after hydroxychloroquine treatment :
Serum adipokine levels before and after hydroxychloroquine treatment :
RESULTS: Forty-one patients (4 males and 37 females, mean age 43 ± 12 years) were includ.
result:
Changes of serum inflammatory factors and adipokines before and after hydroxychloroquine treatment:
Changes of serum inflammatory factors and adipokines before and after hydroxychloroquine treatment:Therefore, HCQ supplementation in SLE patients can improve adipokines leve.
Supplemental HCQ therapy improves adipokines in SLE patien.
There is a study of the relationship between hydroxychloroquine (HCQ) use and the risk of developing heart failure (HF) in rheumatoid arthritis (RA)
Methods: In a nested case-control study, cases were residents of Olmsted County, Minnesota, who developed RA (based on 1987 American College of Rheumatology criteria) from 1980 to 2013 and developed HF after RA ons.
method:
Use HCQ prior to index date/HF diagnosis in RA patients according to HF status :
Use HCQ prior to index date/HF diagnosis in RA patients according to HF status :
Results: The study identified 143 RA cases diagnosed with HF (mean age 68 years, 62% women) and 143 non-HF RA controls (mean age 65 years, 62% wome.
result:
Therefore, in the study, the use of HCQ was not associated with the development of HF in RA patients
In study, HCQ use was not associated with HF in RA patients
references:
references:Wakiya R, Ueeda K, Shimada H, Nakashima S, Kameda T, Miyatake N, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi.
Wakiya R, Ueeda K, Shimada H, Nakashima S, Kameda T, Miyatake N, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi.
Sorour AA, Kurmann RD, Shahin YE, Crowson CS, Achenbach SJ, Mankad R, Myasoedova.
leave a message here
